Background: The Chronic Kidney Disease Epidemiology Collaboration equation for estimation of glomerular filtration rate (eGFR CKD-EPI ) improves GFR estimation compared with the Modification of Diet in Renal Disease Study equation (eGFR MDRD ) but its association with mortality in a nationally representative population sample in the US has not been studied. Methods: We examined the association between eGFR and mortality among 16,010 participants of the Third National Health and Nutrition Examination Survey (NHANES III). Primary predictors were eGFR CKD-EPI and eGFR MDRD .
Background
Decreased kidney function is an independent risk factor for mortality. While measured glomerular filtration rate (GFR) remains the gold standard for assessing decreased kidney function, in routine clinical practice, GFR is usually estimated from serum creatinine by the Modification of Diet in Renal Disease (MDRD) Study equation (eGFR MDRD ). Understanding the association of eGFR categories with clinical outcomes is an important aspect of the chronic kidney disease (CKD) staging system. Accurate classification of individuals with CKD can inform healthcare utilization and therapeutic decision making by reducing false positive diagnoses of CKD while correctly classifying those with CKD to appropriate risk categories [1] .
The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation for estimation of GFR from serum creatinine (eGFR CKD-EPI ) improves GFR estimation compared with the MDRD Study equation [2] . eGFR CKD-EPI , as compared to eGFR MDRD , results in a lower prevalence of decreased eGFR [2] . Recent publications have demonstrated that use of the CKD-EPI equation results in reclassification of individuals previously classified using eGFR MDRD to different eGFR CKD-EPI categories with more appropriate risk stratification [3] [4] [5] [6] . However, the effect of this reclassification from eGFR MDRD categories by CKD-EPI equation on longterm risk prediction in a nationally representative sample of the US population has not been described. The objective of this study was to evaluate the effect of reclassification using eGFR CKD-EPI on the estimated risk of all-cause and cardiovascular disease (CVD) mortality in the US population using data from the Third National Health and Nutrition Examination Survey (NHANES III) and relevant subgroups.
Methods

Study sample
NHANES III is a cross-sectional, multistage, stratified, clustered probability sample of the noninstitutionalized US civilian population conducted during 1988-1994 by the National Center for Health Statistics (NCHS), a branch of the Center for Disease Control and Prevention [7] . In NHANES III, certain subgroups of the population were oversampled including Mexican Americans, nonHispanic blacks and elderly persons to ensure adequate sample sizes of these groups. We limited the study population to 16,010 persons aged 17 years or older who were examined at the mobile examination center (MEC), were not missing serum creatinine data or covariates of interest, and had available mortality follow-up. Mortality follow-up was available for 99.9% of the eligible participants. The protocols for conduct of NHANES were approved by the NCHS institutional review board and informed consent was obtained from all participants. Procedures were followed in accordance with ethical standards of the Johns Hopkins School of Public Health Office of Human Subjects Research and Institutional Review Board.
Measurements
NHANES III procedures have been previously described [7] . Briefly, standardized questionnaires were administered at home and physical examination and laboratory tests specimen collection was performed at the MEC. Self-reported race/ethnicity was categorized as nonHispanic White, non-Hispanic Black, Mexican-American or other. Smoking was defined as either active cigarette smoking, having smoked >100 cigarettes in life, or never having smoked. Participants were considered to have diabetes mellitus if they reported being told by a doctor that they had diabetes at a time other than pregnancy or if they were taking insulin or oral hypoglycemic agents. Cardiovascular disease (CVD) was considered to be present at baseline if the participant reported being informed by a doctor of prior heart attack, congestive heart failure or stroke. Antihypertensive medication use was based on self-report. Blood pressure (BP) was measured using standard techniques and reported as the average of all systolic and diastolic readings. Participants were advised to fast prior to specimen collection but fasting was not required. Overall, 87% of the participants had fasted for ≥ 6 hours prior to blood draw.
Serum creatinine was measured using a kinetic rate Jaffe method. Serum creatinine measurements were recalibrated to standardized creatinine measurements obtained at the Cleveland Clinic Research Laboratory (Cleveland, Ohio) as described previously [standard creatinine = (0.960 x serum creatinine) -0.184] [8] . We calculated eGFR using the isotope dilution mass spectrometry (IDMS)-traceable 4-variable MDRD Study equation and the CKD-EPI equation [2, 9] . There was no difference in eGFR CKD-EPI based on fasting status (0.98 ml/min/1.73 m 2 lower in those fasting ≥6 hours; p = 0.14). We categorized eGFR into the following clinically relevant categories: ≥120, 90-119, 60-89, 30-59 and <30 ml/min/1.73 m 2 . Within each category of eGFR MDRD , individuals were reclassified into three groups based on eGFR CKD-EPI : a) higher eGFR CKD-EPI category; (b) same eGFR category by both eGFR MDRD and eGFR CKD-EPI , and; (c) lower eGFR CKD-EPI category.
C-reactive protein (CRP) was measured by latexenhanced nephelometry (Dade Behring). CRP level was categorized as either undetectable by the assay (<0.22 mg/dL), minimal (0.22-0.99 mg/dL) or elevated (≥1.0 mg/dL). Urinary albumin level was measured by solid-phase fluorescence immunoassay, and urinary creatinine level was measured by the modified kinetic method of Jaffe using a Beckman Coulter Synchron AS/Astra Analyzer (Beckman Coulter, Inc., Fullerton, California). Albuminuria was expressed as urinary albumin-to-creatinine ratio (ACR) and categorized into 3 categories; <30 mg/g, 30-299 mg/g and ≥300 mg/g.
Causes of death
Causes of death were obtained using the NHANES III Linked Mortality Public-use File [10] . This file contains mortality follow-up data on NHANES III participants obtained via National Death Index (NDI) linkage through December 31, 2006. Mortality ascertainment is performed using probabilistic matching between NHANES III and NDI using previously validated methods [10] . Cause of death coding for all U.S. deaths occurring prior to 1999 followed the 9th revision of the International Statistical Classification of Diseases, Injuries, and Causes of Death (ICD-9) guidelines, while all deaths after 1998 followed the 10th revision of the International Statistical Classification of Diseases, Injuries, and Causes of Death (ICD-10) guidelines. All deaths occurring prior to 1999 were recoded from ICD-9 to comparable ICD-10 (I) based cause of death groups [11] . We defined cardiovascular disease mortality using the following cause of death groups: 056 (hypertensive heart disease [I11]), 057 (hypertensive heart and renal disease 
Statistical analysis
All analyses were performed using 6-year MEC sampling weights provided by the National Center for Health Statistics that account for the complex survey design of NHANES III as well as probabilities for non-response. Analyses were performed using survey (svy) commands Stata 10.1 and 11.2. (Stata Corp, www.stata.com) Baseline characteristics were compared across eGFR categories and reclassification status of the participants. Survival analysis techniques were used to analyze the risk of all-cause and CVD mortality. Individuals who were alive on December 31, 2006 were censored in the analyses. Modified Cox proportional hazards regression was used to model the risk of death across eGFR and reclassification categories. Hazard ratios (HR) were calculated to assess risk of death after adjustment for age, race/ethnicity, sex, body mass index, systolic and diastolic BP, antihypertensive medication use, history of diabetes and CVD, smoking status, serum total cholesterol, ACR categories and CRP categories. Poisson regression was used to calculate and display incidence rates with eGFR modeled as a restricted cubic spline with knots at 30, 45, 60, 90 and 120 ml/min/1.73 m 2 .
Reclassification
To assess reclassification we calculated net reclassification improvement (NRI) [12] . Net reclassification improvement (NRI) is a statistic that allows calculation of the effect of reclassification of individuals from one disease category to the other. It is a difference of two ratios; clinically correct reclassification minus clinically incorrect classification. The range of this difference is from −1 to +1 with a negative number reflecting incorrect reclassification and a positive number indication correct reclassification.
For NRI calculations we excluded individuals with eGFR ≥120 ml/min/1.73 m 2 by either equation as the high eGFR in this group reflects low serum creatinine likely from malnutrition, intercurrent illness and low muscle mass [3] . To calculate NRI, we first created cross-tabulation of participants in eGFR MDRD and eGFR CKD-EPI categories stratified by the outcome status (alive or dead). We then calculated the proportion of individuals in each category of eGFR MDRD that are reclassified by eGFR CKD-EPI . Clinically correct reclassification was defined as: proportion of participants reclassified to higher eGFR category by eGFR CKD-EPI among those who are alive + the proportion of participants reclassified to lower eGFR category by eGFR CKD-EPI among those who died. Clinically incorrect reclassification was defined as: proportion of participants reclassified to higher eGFR category by eGFR CKD-EPI among those who died + the proportion of participants reclassified to lower eGFR category by eGFR CKD-EPI among those who are alive. NRI = clinically correct reclassification -clinically incorrect reclassification. Statistical significance for NRI was calculated using bootstrapping with replacement. To account for the confounding effect of age, sex and race on outcomes, we also calculated stratum-specific NRI in these subgroups.
Results
Baseline characteristics
The baseline characteristics of the participants stratified by reclassification status by eGFR CKD-EPI are presented in Table 1 . Overall, the number of participants (population %) reclassified were as follows: 3,464 (26.9%) of the participants were reclassified to a higher eGFR category, 559 (2.2%) were reclassified to a lower eGFR category and 11,987 (70.8%) were not reclassified. There was only 1 participant with eGFR MDRD <30 ml/min/1.73 m 2 who was reclassified upward (data not presented in Table1). Individuals reclassified to higher eGFR CKD-EPI categories were more likely to be younger, female, had lower prevalence of diabetes and CVD, and had lower BP, cholesterol, CRP and less albuminuria. These differences were much more pronounced at lower eGFR categories (<60 ml/min/1.73 m 2 ). Among participants with eGFR MDRD <120 ml/min/1.73 m 2 , no participants below 65 years were reclassified to a lower eGFR CKD-EPI category.
Estimated GFR and the risk of death
There were 3,620 deaths over 215,082 person-years of follow-up (median, 14.3 years). The weighted unadjusted incidence rate for all-cause mortality was higher for eGFR CKD-EPI compared with eGFR MDRD below 90 ml/ min/1.73 m 2 ( Figure 1a ). Within categories of eGFR, the hazards for all-cause mortality adjusted for demographic characteristics, comorbidities, CRP and ACR were higher for eGFR CKD-EPI categories compared with eGFR MDRD categories ( Table 2 ). With both eGFR equations, there was U-shaped association with mortality with higher risk of death for eGFR above 120 ml/min/1.73 m 2 and below 60 ml/min/1.73 m 2 compared with eGFR 90-119 ml/ min/1.73 m 2 . There were few individuals with eGFR <30 ml/min/1.73 m 2 (eGFR MDRD , n = 56; eGFR CKD-EPI , n = 67) and few deaths in individuals with eGFR ≥120 ml/min/1.73 m 2 (eGFR MDRD , n = 228; eGFR CKD-EPI , n = 179). Overall, the trends for association between eGFR categories and CVD mortality (n = 1,540) were very similar to all-cause mortality ( Figure 1b and Table 2 ). Figure 2 displays the unadjusted cumulative incidence of death with reclassification by eGFR CKD-EPI . Those classified upwards to a higher eGFR CKD-EPI category had lower cumulative incidence of mortality while those reclassified downward to lower eGFR CKD-EPI category had higher cumulative incidence of death compared with those not reclassified. Overall, compared with no reclassification, the hazard ratio (HR) of all-cause mortality with reclassification to a higher eGFR CKD-EPI category was 0.34 (95% CI, 0.28-0.41) and with reclassification to a lower eGFR CKD-EPI category was 3.56 (95% CI, 3.04-4.16). After adjustment for age, sex and race/ethnicity, the HR was 0.91 (95% CI, 0.75-1.10) and 1.28 (95% CI, 1.11-1.48) for reclassification to a higher and lower eGFR CKD-EPI category, respectively. 
Reclassification by eGFR CKD-EPI and the risk of death
Net reclassification improvement by eGFR CKD-EPI
To evaluate the effect of reclassification on mortality, we restricted our analysis to individuals with eGFR MDRD and eGFR CKD-EPI <120 ml/min/1.73 m 2 . Table 4 presents the NRI for all-cause and CVD mortality. The overall NRI for eGFR CKD-EPI for all-cause mortality was 0.21 (p < 0.001) and for CVD mortality was 0.22 (p < 0.001). In age stratified analyses, the NRIs was lower as expected but remained substantial for participant age >65 years (0.14 for all-cause and 0.09 for CVD, p < 0.001). The NRI was also significant stratified by sex and most ethnicity groups as well as stratified by sex and limited to older participants (Additional file 1 Table  S1 , NRI 0.09 for men and 0.15 for women age >65 years).
Discussion
In this study of a representative sample of US adults during 18 years of follow-up, eGFR CKD-EPI improved risk stratification. Among those classified as eGFR MDRD [2, 13] . The properties of the CKD-EPI equation result in higher eGFR in younger individuals, whites and females. In NHANES, we noted that reclassification moved individuals with higher comorbidities to a lower eGFR CKD-EPI category and individuals with lower comorbidities to higher eGFR CKD-EPI categories. In the clinically important CKD stage 3 (eGFR MDRD 30-59 ml/ min/1.73 m 2 ), almost 20% of the population was reclassified to a higher eGFR CKD-EPI category. In unadjusted and adjusted analyses, this reclassification was associated with a lower risk of death, suggesting that eGFR CKD-EPI in this range may have clinical significance even without information about other comorbidities. These findings have important implications for both individual clinical risk stratification and screening. A number of recent studies have demonstrated that the use of eGFR CKD-EPI results in improvement in risk classification of individuals. In the Australian Diabetes, Obesity and Lifestyle (AusDiab) Study, 25% of the participants with eGFR MDRD <60 ml/min/1.73 m 2 were reclassified to higher eGFR CKD-EPI category [4] . The risk of death in individuals with eGFR MDRD <60 ml/min/1.73 m 2 reclassified to eGFR >60 ml/min/1.73 m 2 by the CKD-EPI equation was similar to those with eGFR MDRD ≥60 ml/ min/1.73 m 2 (HR, 1.01; 95% CI, 0.62-1.97). In the Atherosclerosis Risk in Communities (ARIC) Study, a prospective cohort of 45-64 year old whites and AfricanAmericans from 4 US communities (N = 13,905), reclassification from eGFR MDRD 30-59 ml/min/1.73 m 2 to eGFR CKD-EPI 60-89 ml/min/1.73 m 2 was associated with a lower risk of all-cause mortality in the unadjusted models but was no longer significant after adjustment for age, sex and race. NRI for all-cause mortality was 0.095 (p < 0.001) [3] . Among participants of Kidney Early Evaluation Program (KEEP), a US screening program for individuals at high risk of chronic kidney disease, 17.5% were reclassified to higher eGFR categories and 2.7% to lower categories. Upward reclassification was associated with lower mortality, downward reclassification was associated with higher mortality and NRI was 0.159 [6] . In a post hoc analysis of the VALIANT trial, eGFR CKD-EPI categories improved risk stratification and the NRI for the composite end point of CVD death, recurrent myocardial infarction, heart failure, or stroke was 0.087 [5] . Our study extends these findings in a study with results generalizable to the US population and quantifies the improvement in risk stratification in African-Americans and Mexican-Americans.
We used NRI to assess the improvement in risk prediction with CKD-EPI equation compared with the MDRD Study equation. The improvement in risk prediction is expected to be relatively small as both equations use the same variables and have the inherent limitation of serum creatinine as a marker of GFR. Traditional methods for risk prediction, such as area under the receiver-operating-characteristic curve (AUC) require large independent associations, often over 2-3 fold, to result in meaningful improvement in AUC [14] [15] [16] . The NRI is particularly well suited when categories are associated with clinical action as is the case for estimated GFR. The NRI was lower in younger age groups despite high reclassification rates, possibly since death rates are low at younger age. Among older age groups (>65 years), NRIs were quite high (0.14 for all-cause and 0.09 for CVD mortality) despite reclassification being lower (11% compared to >30% in younger ages). Notably, the NRIs in the older age group remain significant even after stratification with sex or race/ethnicity. In contrast to ARIC and KEEP, NRIs in NHANES were not positive or statistically significant in those 45-64 years of age. These discrepant findings require further study across a range of populations. We noted increased risk of all-cause and CVD death among individuals with eGFR ≥120 ml/min/1.73 m 2 by either equation compared with eGFR 90-119 ml/min/ 1.73 m 2 after the adjustment for potential confounders ( Table 2 ). The HR was higher for eGFR CKD-EPI than for eGFR MDRD in this category. This association has been noticed in previous studies and replicates the wellknown U-shaped relationship between serum creatinine and mortality. This U-shape likely includes components of low muscle mass and hyperfiltration which cannot be separated using only serum creatinine as a marker of GFR. They persist despite the inclusion of a spline term for serum creatinine in the CKD-EPI equation which reduces the very high eGFRs calculated using the MDRD Study equation.
The strengths of our study includes its large sample size, prospective design, large sample of racial/ethnic minorities, broad age range of the population, rigorous data collection and extensive information on covariates, prior work to standardize serum creatinine, measurement of ACR and CRP, near-complete mortality follow-up using the NDI and large number of events during the followup period. The results of our study are generalizable to the non-institutionalized population of the U.S. Some limitations of our study also deserve mention. GFR was not measured but was estimated using serum creatinine and not all participants were fasting prior to serum creatinine measurement. Nonetheless, serum creatinine and estimated GFR are routinely used measures of kidney function in clinical practice and our data reflect common clinical information. We had relatively few individuals with eGFR MDRD <30 ml/min/1.73 m 2 . Cause of death was ascertained via NDI linkage of NHANES III data and not independently adjudicated and there is potential of misclassification of CVD mortality. Importantly, we did not have information about kidney failure requiring renal replacement therapy, an important outcome that deserves examination in future studies.
Conclusion
The CKD-EPI equation for estimating GFR predicts risk at least as well as the MDRD Study equation in the general US population and improves risk classification of individuals, particularly among those older than 65 years. Our data, in conjunction with previously reported studies, suggest that adoption of CKD-EPI equation for eGFR reporting may improve clinical risk stratification. 
